FDA Issues Complete Response Letter for Toripalimab
In a complete response letter, the FDA asked drug manufacturers Coherus and Junshi Biosciences for a quality process change that the companies say is readily addressable.
Denny Lanfear Junshi Biosciences Jared Weis University Of North Carolina At Chapel Hill Drug Administration Medscape Medical Newscoverage
Source: medscape.com